Intellia Therapeutics Inc (NTLA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $12.14 (-0.98%), Market cap $1.65B, 52-week low–high $6.87 ~ $27.98.
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats ("CRISPR")/CRISPR associated 9 ("Cas9") technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimm
Financial statements, price targets, institutional (13F) holdings and related news for Intellia Therapeutics Inc are updated in real time on BlackAll Trade.
Intellia Therapeutics Inc trades at $12.14 (-0.98%). Real-time quotes and charts are available on BlackAll Trade.
Intellia Therapeutics Inc has a market cap of about $1.65B.
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers cluster